Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
1.150
0.00 (0.00%)
At close: Jun 6, 2025, 4:00 PM
1.120
-0.030 (-2.61%)
After-hours: Jun 6, 2025, 7:56 PM EDT
Biodexa Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
3.32M USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 381.00K | -318.00K | -45.49% |
| Dec 31, 2022 | 699.00K | 121.00K | 20.93% |
| Dec 31, 2021 | 578.00K | 235.00K | 68.51% |
| Dec 31, 2020 | 343.00K | -331.00K | -49.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BDRX News
- 3 days ago - Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes - GlobeNewsWire
- 8 days ago - Shareholder Update - GlobeNewsWire
- 15 days ago - Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting - GlobeNewsWire
- 16 days ago - Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M - GlobeNewsWire
- 26 days ago - Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP - GlobeNewsWire
- 5 weeks ago - Result of General Meeting - GlobeNewsWire
- 7 weeks ago - Notice of General Meeting - GlobeNewsWire
- 2 months ago - Preliminary Results for the Year Ended 31 December 2024 - GlobeNewsWire